Overview

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This is a phase II trial of reduced intensity conditioning with Bu/Flu/ATG in pediatric patients with hematologic malignancies at high risk for transplant related mortality with standard transplantation. Patients qualify based on organ system dysfunction, active but stable infection, history of previous transplant or late stage disease. We plan to enroll 45 patients through the Pediatric Blood and Marrow Transplant Consortium (PBMTC) and anticipate that the outcome of the trial will pave the way for phase II or III disease specific protocols addressing efficacy of the approach compared to standard transplant approaches in better risk patients.
Phase:
Phase 2
Details
Lead Sponsor:
University of Utah
Treatments:
Antilymphocyte Serum
Busulfan
Cyclosporine
Cyclosporins
Fludarabine
Fludarabine phosphate
Mycophenolate mofetil
Mycophenolic Acid
Thymoglobulin